Tesamorelin for Sale: Research Guide, Trial Data, and Sourcing

May 22, 2026
11:34 am

What Is Tesamorelin?

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid group added to the N-terminus. Developed by Theratechnologies, it is the only FDA-approved GHRH analog — approved under the brand name Egrifta® for HIV-associated lipodystrophy in 2010. Beyond its approved indication, tesamorelin has attracted substantial research interest for its effects on body composition, metabolic function, and age-related growth hormone decline.

Unlike direct GH replacement, tesamorelin preserves the pulsatile pattern of endogenous GH secretion, a pharmacological advantage that researchers consider important for mimicking physiological conditions in study designs.

Mechanism of Action

Tesamorelin activates GH secretion through the hypothalamic-pituitary axis:

GHRH Receptor (GHRHR) Agonism: Binds and activates pituitary somatotroph GHRH receptors, triggering GH synthesis and release
cAMP Signaling: Activates adenylyl cyclase cascade, increasing intracellular cAMP and PKA activity in somatotrophs
Preserved Pulsatility: Enhances amplitude of endogenous GH pulses rather than producing continuous supraphysiological levels
IGF-1 Cascade: Downstream GH stimulation increases hepatic IGF-1 production, the primary mediator of GH’s anabolic effects
Lipolytic Effects: GH-mediated activation of hormone-sensitive lipase in visceral adipose tissue, particularly relevant for lipodystrophy research

Clinical Research Data

HIV-Associated Lipodystrophy (FDA-Approved Indication)

Phase 3 trials leading to FDA approval demonstrated robust effects:

Mean visceral adipose tissue (VAT) reduction of 15–20% from baseline at 26 weeks vs. placebo
Significant improvements in trunk fat ratio and waist circumference
Trunk-to-limb fat ratio improved vs. stable placebo group
Benefits observed across HIV-positive patients on antiretroviral therapy

Age-Related GH Decline Research

Studies in healthy older adults (60+ years) have investigated tesamorelin for somatopause:

IGF-1 levels increased to levels comparable to those of young adults in multiple trials
Improved lean mass and reduced total body fat in 6-month protocols
Improvements in cognitive function (verbal memory, executive function) observed in a 2019 randomized trial (n=152 older adults with mild cognitive impairment)
Favorable changes in cardiovascular risk markers including triglycerides and LDL in metabolic sub-studies

NAFLD/Metabolic Research

Pilot studies show tesamorelin reduces liver fat fraction in patients with non-alcoholic fatty liver disease
Improved hepatic insulin sensitivity markers in metabolic syndrome research

Dosage Reference for Research

Study Context	Dose	Frequency	Duration
FDA-approved (lipodystrophy)	2mg	Daily SC	26+ weeks
Aging/cognitive research (human)	1–2mg	Daily SC	20–26 weeks
Rodent models	100–300 µg/kg	Daily SC	4–12 weeks

Research reference only. Not dosing guidance for human use.

Tesamorelin vs. CJC-1295 — Research Comparison

Parameter	Tesamorelin	CJC-1295 (Without DAC)
Sequence	Full GHRH (44 aa) + trans-3-hexenoic acid	Modified GHRH 1-29 (30 aa)
FDA approval	Yes (Egrifta — HIV lipodystrophy)	No
Half-life	~26 minutes	~30 minutes (without DAC)
Clinical data depth	Extensive (Phase 3 + approval)	Phase 1/2 only
Primary use in research	Lipodystrophy, aging, cognition	GH secretion, body composition

Where to Buy Tesamorelin for Research

When sourcing tesamorelin for laboratory research, evaluate suppliers on:

HPLC purity ≥99% with detailed COA
Mass spectrometry confirmation of full 44-aa sequence and N-terminal modification
Sterility and endotoxin testing documentation
Lyophilized format for −20°C long-term stability

Tesamorelin Research Products

HPLC Verified

Tesamorelin 10mg

Purity: 99%+ HPLC

Format: Lyophilized Powder

Testing: Third-Party COA

$140

Buy Now